# Scitech Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scitech-pharma

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.scitech-pharma.com
- Total disclosed funding: $14M
- Latest round: Series A (Apr 27, 2024)
- Investors on record: 3

## About

Established in 2015 and based in Beijing, China, Scitech Pharma is drug development company engaged in the design and development of innovative drugs using artificial intelligence. The company has developed a pipeline of new drugs in the fields of oncology, autoimmune systems, and central nervous system diseases. The company has 103 authorized patents, including 22 domestic patents and 81 foreign patents. Meanwhile, it has a research and biological experiment base covering an area of 20,000 square meters, including 11 laboratories including chemical laboratory, biological laboratory, preparation laboratory and a drug screening and drug design calculation center. In April 2024, it raised over CNY 100 million in a series A+ round of funding.

The company specializes in the research and development of small molecule drugs. The company's product portfolio includes candidates for various stages of drug development, with one drug candidate in Phase II clinical trials (ST-1898, a multi-targeted tyrosine kinase inhibitor to tackle tumor therapy) and others in Phase I. The company mainly develops drugs for oncology, autoimmune diseases and central nervous system disorders. Utilizing its proprietary SigmaHIT® software, Scitech Pharma provides advanced drug design and development services, targeting unmet medical needs both domestically and internationally.

The company generates revenue by advancing its drug candidates through clinical trials and partnering with other pharmaceutical companies for the development and commercialization of its products.

The company will use its recent A+ round of funding which raised in April 2024 to accelerate the clinical trials of its anti-tumor innovative drugs ST-1898 and ST-1703, aiming to bring effective treatment options to patients suffering from various types of cancer.

## Funding rounds

- Series A, Apr 27, 2024, $14M — Tigermed, Elikon Venture, Shanghai Zhizhong Private Equity Fund Management

## Investors

- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series A
- Shanghai Zhizhong Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-zhizhong-private-equity-fund-management) — Series A